



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Share Trading Contact Information

Melbourne, 22 January 2016:

BioDiem would like to inform existing shareholders and other interested parties that Leydin Freyer (the Company's accountants) maintains a Register of Interest which records buying and selling expressions of interest for BioDiem ordinary shares. Once agreement has been reached between interested parties, Leydin Freyer will arrange settlement of the transactions and execute all necessary documentation with the Company's Share Registry, Computershare.

If existing shareholders have enquiries regarding their current share holdings, then they are encouraged to contact Computershare for details.

Contact Information:

Share Registry - Computershare Investor Services Pty Ltd

Yarra Falls, 452 Johnston Street
Abbotsford
Victoria 3067

Telephone: + 61 3 9415 4000
Investor Queries (within Australia): 1300 850 505
Facsimile: +61 3 9473 2500
Website: www.computershare.com.au

Share Trading Contact Information

Contact: Leydin Freyer Corp Pty Ltd
Email: Melanie Leydin mleydin@leydinfreyer.com.au
Phone: 03 9692 7222
Address: Level 4
100 Albert Road
South Melbourne
VIC 3205

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit www.opalbiosciences.com.